14C-radiolabeled (radiocarbon) drug studies are central to defining the disposition of therapeutics in clinical development. Concerns over radiation, however, have dissuaded investigators from conducting these studies as often as their utility may merit. Accelerator mass spectrometry (AMS), originally designed for carbon dating and geochronology, has changed the outlook for in-human radiolabeled testing.
PRA understands how cerebrospinal fluid (CSF) sampling benefits our clients’ early phase trials. We regularly conduct CSF sampling to collect key PK…
PRA Successfully Delivers A Complex Phase I Psoriasis Study
Exceptional Support and Innovative Strategies Combat Study Challenges.
PRA’s Vaccine Solutions group understands the unique challenges and characteristics of vaccine development. Right from the start, our experts will…